Contract Manufacturing, In-Vivo and Life Science

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Contract Manufacturing

In-Vivo

Life Science

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

MARCH 2, 2021

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim.

In-Vivo

In-Vivo Contract Manufacturing Bioinformatics Clinical Development

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval

FDA Approval Manufacturing In-Vivo Trials

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical Research Informer

Identify and Validate Innovative Peptides for the Treatment of Obesity

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

Webinars

Stay Connected